CCLA Investment Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-1,423,010
Closed -$133M 62
2024
Q3
$133M Hold
1,423,010
2.04% 13
2024
Q2
$133M Buy
1,423,010
+16,296
+1% +$1.44M 2.04% 13
2024
Q1
$134M Buy
1,406,714
+1,405,319
+100,740% +$118M 2.06% 13
2023
Q4
$107M Sell
1,395
-1,279,930
-100% -$89.1M 1.75% 27
2023
Q3
$88.8M Buy
1,281,325
+25,770
+2% +$2.07M 1.66% 28
2023
Q2
$118M Buy
1,255,555
+92,090
+8% +$8M 2.11% 12
2023
Q1
$96.1M Buy
1,163,465
+96,873
+9% +$7.61M 1.89% 19
2022
Q4
$79.6M Buy
1,066,592
+259,051
+32% +$20M 1.8% 23
2022
Q3
$66.9M Buy
+807,541
New +$77.7M 1.62% 30
2022
Q1
$94.6M Buy
802,978
+12,198
+2% +$1.37M 1.7% 23
2021
Q4
$102M Sell
790,780
-47,157
-6% -$5.5M 1.68% 25
2021
Q3
$94.9M Buy
837,937
+84,739
+11% +$9.67M 1.57% 27
2021
Q2
$78M Buy
753,198
+188,568
+33% +$17.8M 0.95% 39
2021
Q1
$47.2M Buy
564,630
+132,070
+31% +$11.2M 0.94% 51
2020
Q4
$39M Buy
432,560
+3,790
+0.9% +$314K 0.88% 55
2020
Q3
$34.2M Buy
+428,770
New +$33.5M 0.93% 49

Other funds holding EW

CCLA Investment Management's EW Position: Q4 2024 in Review

CCLA Investment Management sold out of Edwards Lifesciences (EW) in Q4 2024, closing a stake of 1,423,010 shares — an estimated $133M sold.

CCLA Investment Management first reported a position in EW in Q3 2020 and held it in 16 quarters. The position peaked at $134M in Q1 2024. 1,228 funds tracked by Wall St. Rank hold EW as of Q4 2024.

  • CCLA Investment Management reported no remaining Edwards Lifesciences position as of Q4 2024 after selling out during the quarter.
  • CCLA Investment Management sold 1,423,010 Edwards Lifesciences shares in Q4 2024, an estimated $133M.
  • CCLA Investment Management first reported a position in Edwards Lifesciences in Q3 2020 and held it in 16 quarters.
  • CCLA Investment Management's Edwards Lifesciences position peaked at $134M in Q1 2024.
  • 1,228 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2024.

Based on CCLA Investment Management's 13F filing for Q4 2024, filed 14 Jan 2025.